Plus TherapeuticsPSTV
PSTV
About: Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Employees: 21
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.11% more ownership
Funds ownership: 11.38% [Q3] → 11.49% (+0.11%) [Q4]
0% more funds holding
Funds holding: 10 [Q3] → 10 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
20% less capital invested
Capital invested by funds: $981K [Q3] → $780K (-$201K) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5.50
665%
upside
Avg. target
$11.50
1,499%
upside
High target
$20
2,680%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo 47% 1-year accuracy 41 / 87 met price target | 2,680%upside $20 | Buy Maintained | 21 Apr 2025 |
D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target | 1,151%upside $9 | Buy Maintained | 28 Mar 2025 |
HC Wainwright & Co. Sean Lee 57% 1-year accuracy 17 / 30 met price target | 665%upside $5.50 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 4 articles about PSTV published over the past 30 days
Positive
Zacks Investment Research
1 week ago
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee.
Neutral
GlobeNewsWire
2 weeks ago
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ
Positive
Zacks Investment Research
4 weeks ago
Plus (PSTV) Upgraded to Buy: Here's What You Should Know
Plus (PSTV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Seeking Alpha
1 month ago
Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.
Negative
Zacks Investment Research
1 month ago
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.70 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. “Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs,” said Marc H.
Positive
Zacks Investment Research
1 month ago
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company's new proprietary name, REYOBIQ™, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ™ must be submitted once the marketing application (NDA) is submitted.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.
Charts implemented using Lightweight Charts™